<DOC>
	<DOCNO>NCT00003125</DOCNO>
	<brief_summary>RATIONALE : Vaccines may make body build immune response kill tumor cell . Colony-stimulating factor sargramostim may increase number immune cell . Interleukin-2 may stimulate person 's white blood cell kill cancer cell . Combining vaccine therapy , sargramostim , interleukin-2 may kill cancer cell . PURPOSE : Randomized phase II trial study effectiveness vaccine therapy , sargramostim , interleukin-2 treating patient advance tumor .</brief_summary>
	<brief_title>Vaccine Therapy , Interleukin-2 , Sargramostim Treating Patients With Advanced Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate safety sequentially administer vaccinia-carcinoembryonic antigen ( CEA ) vaccine ALVAC-CEA vaccine ( CEA-Avipox vaccine ) two schedule addition sargramostim ( GM-CSF ) plus minus interleukin-2 ( IL-2 ) patient CEA express tumor . II . Compare CEA-specific cellular immune response cancer patient randomize receive single vaccination vaccinia-CEA vaccine follow three boost ALVAC-CEA vaccine ( V-A-A-A ) reverse vaccination sequence ( A-A-A-V ) . III . Determine whether addition GM-CSF alone IL-2 enhances immune response sequentially administer vaccinia-CEA vaccine ALVAC-CEA vaccine . IV . Compare enzyme link immunosorbent assay ELISPOT lymphoproliferative cytotoxicity assay measure CEA-specific T lymphocyte immune response . OUTLINE : This two-stage , partially randomize study . In stage one , patient randomize arm I II . Arm I : Patients receive vaccinia-carcinoembryonic antigen ( CEA ) vaccine intradermally day 1 course 1 ALVAC-CEA vaccine ( CEA-Avipox vaccine ) intramuscularly ( IM ) day 1 course 2-4 . Each course last 28 day . Arm II : Patients receive ALVAC-CEA vaccine ( CEA-Avipox vaccine ) IM day 1 course 1-3 vaccinia-CEA vaccine intradermally day 1 course 4 . Each course last 28 day . Patients arm I II continue 28-day course month 6 receive 3-month course 2 year absence disease progression unacceptable toxicity . In stage two , patient enrol successively arms III IV . Arm III : Patients receive vaccine accord whichever schedule ( arm I II ) find superior plus sargramostim ( GM-CSF ) subcutaneously ( SC ) day 1-4 course . Each course last 28 day . Arm IV : Patients receive vaccine plus GM-CSF arm III interleukin-2 SC daily day 7-11 course . Each course last 28 day . Patients arm III IV continue 28-day course month 6 receive 3-month course 2 year absence disease progression unacceptable toxicity . If 2 patient either arm III IV experience dose limit toxicity , accrual study stop . Otherwise , best response among 4 arm determine HLA-A2 positive patient enrol arm total 6 HLA-A2 positive patient advance disease 6 HLA-A2 positive patient NED ( without radiographic clinical evidence tumor ) treat . If one regimen equally superior , least toxic regimen choose accrual . Patients follow 28 day follow last vaccination . PROJECTED ACCRUAL : A minimum 24 patient ( 6 HLA-A2 positive 3 HLA-A2 negative patient per arm ) accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm malignancy stage IV and/or high risk recurrence despite standard treatment Stage IV malignancy surgically render free macroscopic tumor allow current available treatment likely offer survival advantage result significant palliation If high risk recurrence , must estimate recurrence rate least 75 % follow definitive therapy , : Postresection pancreatic cancer Gastric cancer regional lymph node involvement Node positive stage II stage III esophageal cancer Stage IIIA IIIB nonsmall cell lung cancer Breast cancer least 10 positive axillary node Must low tumor burden evidence disease Must evidence prior vaccinia ( smallpox immunization ) Must CEA express type tumor serum CEA elevation 10 great course disease No CNS metastases Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 Menopausal status : Not specify Performance status : ECOG 01 Life expectancy : At least 6 month Hematopoietic : Absolute granulocyte count least 1,500/mm3 WBC least 3,000/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 2 time upper limit normal ( ULN ) SGOT SGPT great 4 time ULN Renal : Creatinine great 2.0 mg/dL OR Creatinine clearance least 50 mL/min Other : HIV negative No uncontrolled seizure disorder , encephalitis , multiple sclerosis No history allergy untoward reaction prior vaccination vaccinia virus No prior concurrent diagnosis alter immune function , include eczema , atopic dermatitis , autoimmune disease systemic lupus erythematosus , Sjogren 's syndrome , scleroderma , myasthenia gravis , Goodpasture 's syndrome , Addison 's disease , Hashimoto 's thyroiditis , active Graves ' disease Must maintain reasonable state nutrition , consistent weight maintenance No frequent vomit severe anorexia Must able avoid close contact child 3 year young , pregnant woman , individual eczema history eczema open skin condition , immunosuppressed individual least 2 week vaccination No serious concurrent medical illness include inflammatory bowel disease , Crohn 's disease , ulcerative colitis , active diverticulitis Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception least 6 month study PRIOR CONCURRENT THERAPY : Must recover toxic effect prior therapy Biologic therapy : Prior vaccinia immunization require No concurrent biologic therapy No concurrent immunotherapy Chemotherapy : At least 4 week since prior chemotherapy ( 6 week since prior nitrosoureas mitomycin ) No concurrent chemotherapy Endocrine therapy : Physiologic replacement steroid allow No concurrent hormonal therapy Radiotherapy : No prior radiotherapy 50 % nodal group Surgery : At least 3 week since prior major surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage III gastric cancer</keyword>
	<keyword>stage IV gastric cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage II pancreatic cancer</keyword>
	<keyword>stage III pancreatic cancer</keyword>
	<keyword>stage II esophageal cancer</keyword>
	<keyword>stage III esophageal cancer</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
</DOC>